The Therapeutic Goods Administration (TGA) consultation, “Consultation: on increasing transparency of Good Manufacturing Practice (GMP) inspection outcomes”, ran from 10 June 2026 to 13 July 2026. It sought feedback on a proposal to increase transparency of GMP compliance for manufacturers of pharmaceutical products on the TGA website.
The consultation is now closed. As at 12 August 2026, the TGA consultation page states that submissions received by the deadline will be considered and that the decision will be made available through the TGA consultation hub. Manufacturers should therefore avoid treating the proposal as an implemented requirement or assuming a final publication model before the TGA communicates its decision.
Nevertheless, the consultation is an important quality and governance signal. It explicitly asks for views on how GMP certificates and inspection outcomes should be displayed and accessed; how published information can remain clear and accurate without disclosing confidential information; and the benefits or impacts of publication. For organisations within the Australian supply chain, this creates a practical reason to review whether their GMP compliance narrative would withstand external visibility as well as regulatory scrutiny.
What the TGA consulted on
The TGA’s stated proposal concerns the transparency of GMP compliance of manufacturers of pharmaceutical products. The authority sought comments to inform decisions about the scope, format and presentation of information published on its website.
| Official consultation topic | Why it matters to manufacturers |
|---|---|
| Display and access to GMP certificates and inspection outcomes | Information that has historically been handled primarily in regulatory interactions may become easier for customers, partners and other stakeholders to locate and interpret. |
| Clarity, accuracy and confidentiality | The consultation recognises the need to present information accurately and avoid disclosure of confidential information. This makes factual precision and approved external messaging important governance issues. |
| Benefits and impacts of publication | Manufacturers, sponsors and supply-chain partners may experience operational, commercial and reputational effects depending on the eventual approach adopted by the TGA. |
The consultation page does not, by itself, establish the final data fields, publication thresholds, implementation date, transition arrangements or consequences for individual manufacturers. Those points should not be inferred from the consultation notice.
Why this matters beyond inspection day
GMP inspection readiness is often framed as the ability to demonstrate control during an inspection: sound documentation, effective investigations, robust CAPA, appropriate quality oversight and timely escalation. Greater transparency would add a related leadership question: can the organisation explain its quality status consistently, accurately and with appropriate context when information is seen outside the inspection process?
This is not an argument for creating a parallel “public compliance” system. The quality management system should remain the authoritative source for the site’s GMP evidence, decisions and records. The more useful response is to confirm that existing governance reliably connects inspection activity, regulatory correspondence, quality risk management (QRM), CAPA, management review and external communications.
For senior management, the potential significance is particularly clear where a manufacturing site supports multiple products, sponsors, markets or legal entities. A published item may be read by audiences that do not have access to the full inspection context. Good governance therefore depends on knowing who owns the facts, who may interpret them, and how the organisation prevents contradictory statements across Quality Assurance, Regulatory Affairs, Manufacturing, commercial teams and corporate communications.
Regulatory facts and practical readiness actions
What is confirmed by the TGA
- The TGA consulted on increasing transparency of GMP compliance of manufacturers of pharmaceutical products on the TGA website.
- The consultation ran from 10 June 2026 until 13 July 2026.
- The TGA requested views on the display and access of GMP certificates and inspection outcomes, clear and accurate presentation without disclosure of confidential information, and potential benefits or impacts.
- The TGA states that it will consider submissions received by the deadline and make its decision available on the TGA consultation hub.
What GuideGxP recommends
- Do not pre-empt the final TGA decision. Track the consultation hub and assess the published decision when available.
- Map all material GMP compliance information held across Quality, Regulatory Affairs, Manufacturing and local affiliate functions. Identify the controlled source, current status, record owner and approval route for each item.
- Review inspection-response governance. Confirm that commitments, corrective actions, due dates, effectiveness checks and regulatory updates have a clear accountable owner and are traceable to approved records.
- Perform a focused data-quality review of information that could be externally interpreted, including legal manufacturer names, site addresses, manufacturing responsibilities, GMP certificate details and inspection-related status information.
- Test executive escalation and communications procedures using plausible scenarios, such as external stakeholder queries about an inspection outcome or an apparent discrepancy between public information and a customer statement.
- Ensure confidentiality review is embedded in the process for any external response. This should cover commercially sensitive information, third-party information and content that requires regulatory or legal assessment.
A pragmatic readiness plan
A proportionate programme does not require a major new project. For most established manufacturers, a short cross-functional assessment can establish the baseline and identify gaps.
- Assign executive sponsorship and a single co-ordinator. Quality should lead the factual GMP assessment, with Regulatory Affairs, Manufacturing, Legal and Communications involved according to the organisation’s structure.
- Establish the evidence baseline. Create a controlled inventory of GMP certificates, inspection correspondence, inspection outcome records, commitments, CAPA status and relevant product or site responsibility data.
- Check consistency, not just completeness. Compare controlled records with the information used in customer qualification packs, technical agreements, tender responses, corporate materials and regulatory submissions. Resolve discrepancies through the appropriate quality and change-control processes.
- Define an external-information decision tree. Specify who verifies facts, who approves any statement, which functions must be consulted, and when escalation to senior management is required. The process should distinguish factual confirmation from interpretation or speculation.
- Strengthen inspection follow-through. Confirm that inspection commitments are translated into measurable actions, that delays are escalated, and that CAPA effectiveness is evaluated rather than assumed.
- Prepare leaders for context-based questions. Senior management should understand the organisation’s current regulated status, material remediation activity, relevant risks and the boundaries of information that may be discussed externally.
Questions for QA, QP and senior management
- Can we identify the approved, current source for every material statement about our GMP status?
- Are inspection commitments and CAPA progress visible to the right governance forum before overdue actions become an external issue?
- Could a customer-facing team inadvertently use outdated or incomplete GMP information?
- Do our technical agreements and supplier-management arrangements clearly define notification, co-operation and communications expectations?
- Can the QP, Quality leadership and Regulatory Affairs explain any material inspection-related matter using the same verified facts?
- Have we differentiated a regulatory fact from an internal assessment, a remediation plan or an aspirational completion date?
What to watch next
The next material regulatory event is the TGA’s decision following consideration of consultation submissions. Until the authority publishes that decision, organisations should treat the consultation as a signal to improve information governance and inspection follow-through, rather than as a new binding disclosure obligation.
The strongest preparation is not polished messaging. It is a mature pharmaceutical quality system in which inspection evidence is complete, CAPA is effective, responsibilities are unambiguous and externally relevant information can be verified quickly. If the TGA adopts a more transparent model, those capabilities will help manufacturers respond with discipline. If the eventual model is narrower than anticipated, the same work will still strengthen compliance oversight and stakeholder confidence.
